CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 52 enrolled
Drug / intervention
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00869141
NCT00869141Phase 4Completed

Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

University of California, Los Angeles·interventional·Posted Mar 25, 2009·Updated Dec 30, 2015

In Brief

A Phase 4 clinical trial evaluating glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide) for Glaucoma. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the occurrence rate of the high pressure phase and the final pressure outcomes between patients treated with glaucoma medication prior to the expected onset of the high pressure phase to those patients who have glaucoma medication started at the onset of the high pressure phase. The investigators hypothesize that if glaucoma medications are started prior to the expected onset of high pressure phase, the high pressure phase will not occur as frequently and the ultimate pressure level will be lower than if the glaucoma medications are started at the onset of this phase.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 25, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.3 years ago

Interventions

glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)drug

Subjects may receive glaucoma medications after Ahmed valve implantation